950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial

Bahce, I.; Dickhoff, C.; Schneiders, F.L.; Veltman, J.; Heineman, D.J.; Hashemi, S.; Fransen, M.; Vrijmoet, A.; Houda, I.; Ulas, E.; Ven, P. van de; Bouwhuis, N.; Meijboom, L.; Oprea-Lager, D.; Vallejo, Jesús G.; Gruijl, T.D. de; Radonic, T.; Senan, S.

doi:10.1016/j.annonc.2022.07.1076

Cited by 11 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was high interrater agreement in terms of study selection (κ = 0.979; p = .021). Table 1 displays pertinent details of each study 13–78 ; patients most commonly had stage III disease and received two to four cycles of various ICIs.…”

Section: Resultsmentioning

confidence: 99%

Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis

Verma

Gay

et al. 2023

Cancer

View full text Add to dashboard Cite

Background Neoadjuvant immunotherapy (nIT) is a rapidly emerging paradigm for advanced resectable non‐small cell lung cancer (NSCLC). The objectives of this PRISMA/MOOSE/PICOD‐guided systematic review and meta‐analysis were (1) to assess the safety and efficacy of nIT, (2) to compare the safety and efficacy of neoadjuvant chemoimmunotherapy (nCIT) versus chemotherapy alone (nCT), and (3) to explore predictors of pathologic response with nIT and their association with outcomes. Methods Eligibility was resectable stage I–III NSCLC and the receipt of programmed death‐1/programmed cell death ligand‐1 (PD‐L1)/cytotoxic T‐lymphocyte–associated antigen‐4 inhibitors before resection; other forms and modalities of neoadjuvant and/or adjuvant therapies were allowed. For statistical analysis, the Mantel–Haenszel fixed‐effect or random‐effect model was used, depending on the heterogeneity (I2). Results Sixty‐six articles met the criteria (eight randomized studies, 39 prospective nonrandomized studies, and 19 retrospective studies). The pooled pathologic complete response (pCR) rate was 28.1%. The estimated grade ≥3 toxicity rate was 18.0%. Compared with nCT, nCIT achieved higher rates of pCR (odds ratio [OR], 7.63; 95% confidence interval [CI], 4.49–12.97; p < .001), progression‐free survival (PFS) (hazard ratio [HR] 0.51; 95% CI, 0.38–0.67; p < .001), and overall survival (OS) (HR, 0.51; 95% CI, 0.36–0.74; p = .0003) but yielded similar toxicity rates (OR, 1.01; 95% CI, 0.67–1.52; p = .97). The results remained robust on sensitivity analysis when all retrospective publications were removed. pCR was associated with improved PFS (HR, 0.25; 0.15–0.43; p < .001) and OS (HR, 0.26; 95% CI, 0.10–0.67; p = .005). PD‐L1 expressors (≥1%) were more likely to achieve a pCR (OR, 2.93; 95% CI, 1.22–7.03; p = .02). Conclusions In patients with advanced resectable NSCLC, neoadjuvant immunotherapy was safe and efficacious. nCIT improved pathologic response rates and PFS/OS over nCT, particularly in patients who had tumors that expressed PD‐L1, without increasing toxicities. Plain Language Summary This meta‐analysis of 66 studies showed that neoadjuvant immunotherapy for advanced resectable non‐small cell lung cancer is safe and efficacious. Compared with chemotherapy alone, chemoimmunotherapy improved pathologic response rates and survival, particularly for patients who had tumors that expressed programmed cell death ligand‐1, without increasing toxicities.

show abstract

Section: Resultsmentioning

confidence: 99%

Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis

Verma

Gay

et al. 2023

Cancer

View full text Add to dashboard Cite

show abstract

“…The combination of nivolumab plus ipilimumab had higher MPR rates (50% vs. 24%) and pCR rates (38% vs. 10%) compared to nivolumab in the phase II Neostar trial [ 39 ]. The combination of nivolumab plus ipilimumab with chemoradiotherapy was associated with a pCR rate of 63% in surgery in the recent phase II INCREASE trial, including patients with resectable and borderline resectable NSCLC [ 40 ]. Considering the higher benefit of combination in the Neostar trial and the feasibility of using nivolumab plus ipilimumab in combination with chemotherapy as in the Checkmate 9LA study in the metastatic stage [ 41 ], further research with combination immunotherapy and chemotherapy is expected.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

Guven,

Sahin,

Kilickap

2023

Cancers

View full text Add to dashboard Cite

Background: After the success of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), the benefit of neoadjuvant chemoimmunotherapy was compared with chemotherapy for localized NSCLC in several trials. However, the available studies had variable study designs, and study cohorts had limited follow-up times. Therefore, we conducted a systematic review and meta-analysis to evaluate the benefit of adding immunotherapy to neoadjuvant chemotherapy in patients with localized NSCLC. Methods: We conducted a systematic review using Pubmed, Web of Science, and Scopus databases for studies published until 5 December 2023. This protocol was registered in the PROSPERO database (Registration Number: CRD42023466337). We performed the meta-analyses with the generic inverse-variance method with a fixed effects model. Results: Overall, 7 studies encompassing 2993 patients were included in the analyses. The use of neoadjuvant chemoimmunotherapy was associated with a 41% reduction in the risk of progression or death compared to neoadjuvant chemotherapy (HR: 0.59, 95% CI: 0.52–0.66, p < 0.0001) and a lower risk of death (HR: 0.67, 95% CI: 0.55–0.82, p < 0.0001). The neoadjuvant chemoimmunotherapy improved pCR rates compared to chemotherapy (21.8% vs. 3.8%, OR: 7.04, 95% CI: 5.23–9.47, p < 0.0001), while high-grade adverse events were higher with neoadjuvant chemoimmunotherapy (OR: 1.18, 95% CI: 1.02–1.36, p = 0.0300). Conclusions: The available evidence demonstrates a statistically significant and clinically meaningful event-free survival benefit and possibly an overall survival benefit with neoadjuvant chemoimmunotherapy with a slight increase in high-grade toxicities.

show abstract

“…В исследовании II фазы INCREASE изучалась возможность включения комбинации ипилимумабниволумаб в схемы ведения пациентов с химиолучевой терапией [19].…”

Section: эффективность неоадъювантной терапии ипилимумаб плюс ниволум...unclassified

Results of the ESMO Congress: Immunotherapy for NSCLC

Andreev,

Zavyalov,

Varlamova

2023

A.I. Burnasyan Federal Medical Biophysical Center Clinical Bull

View full text Add to dashboard Cite

Every year, more than 1.5 million people die from lung cancer (LC) worldwide. In a number of industrialized countries, LC is the dominant oncological disease. The beginning of autumn 2022 was marked by a regular landmark event in the professional environment of oncologists: the Annual Congress of the European Society for Medical Oncology (ESMO) was held in Paris. The congress presented and discussed innovative developments in immunotherapy for patients with advanced NSCLC. The purpose of this work was to summarize the current clinical developments in combined immunotherapy for advanced NSCLC discussed at the ESMO Annual Congress – September 2022: IFCT-1701 studies; KEYNOTE-407; KEYNOTE-189; IPSOS; INCREASE. The systematic search for effective antitumor immunodrugs continues, and a comprehensive modernization of the protocols for their use is being carried out. This allows us to hope for a cardinal increase in life expectancy and improvement in its quality in patients with NSCLC, even at the most advanced stages.

show abstract

950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial

Cited by 11 publications

References 0 publications

Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis

Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

Results of the ESMO Congress: Immunotherapy for NSCLC

Contact Info

Product

Resources

About